Skip to content
Vaccine-focused biopharma Dynavax Technologies (DVAX) has announced a collaboration to develop a universal influenza (flu) vaccine with the Icahn School of Medicine at Mount Sinai.Mount Sinai’s work in this area is funded under a contract award from the National Institute of Allergy and Infectious Diseases (NIAID), as part of the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program.The Mount Sinai CIVICs team will evaluate a novel approach they have developed called chimeric hemagglutinin (cHA) designed to protect against all strains of influenza in combination with Dynavax’s CpG 1018TM adjuvant.Adjuvants are added to a vaccine to boost the immune response to produce more antibodies and longer-lasting immunity, thus minimizing the dose of antigen needed. They can also enhance vaccine efficacy by helping to modify the immune response by particular types of immune system cells.The development program will support an Investigational New Drug (IND) application for Phase I clinical trials.There are no approved universal flu vaccines. The effectiveness of seasonal influenza vaccine ranges...
Daimler will stop building Mercedes-Benz sedans in the United States and Mexico as it seeks deeper cuts after posting a smaller-than-expected quarterly loss. The German automaker will halt output of its Mercedes-Benz C-Class sedan in Tuscaloosa, Alabama, leaving the plant producing sport utility vehicles (SUVs) only, it said. "Daimler pre-released better-than-consensus second-quarter numbers," Jefferies analyst Philippe Houchois said in a note....
Undeniably, the novel coronavirus is one of the worst catastrophes in American history. And yet, I can't help but think that the pandemic made Zynga (NASDAQ:ZNGA) great again. Proponents of the mobile video gaming specialist will argue that Zynga stock was already great. However, shares are still down a good-sized discount from their all-time high. So, as Vice President Mike Pence might say, can ZNGA be made great again … again?Source: JHVEPhoto / Shutterstock.com Looking at the situation from a bird's eye view, the evidence strongly points to a hearty, Trump country yee-haw. As the coronavirus started infecting Americans at a blistering rate, a few governors made the painful but critical decision to shut down their state's economies. Later, as New York became the global epicenter for Covid-19, most states had followed suit.Of course, this suited Zynga stock just fine. From its March doldrums, shares began rocketing toward low-earth orbit. Granted,...
Virgin Galactic (NYSE:SPCE) has lifted off, but is today's enthusiasm misplaced? Let's examine what's happening off and on the price chart and see how today's investors can better prepare for a more profitable tomorrow.Source: Christopher Penler / Shutterstock.com Space tourism operator Virgin Galactic is going places. Maybe not today, but it's in the not-so-distant future. And right now, investors are taking stock in SPCE and sending shares higher by nearly 14% Thursday.Oh, those silly fanatical bulls, right? Nope. Today's rally in SPCE is anything but just another confidently and overexcited performance in an overbought market led by Apple (NASDAQ:AAPL), Tesla (NASDAQ:TSLA), Shopify (NYSE:SHOP) or some other large-cap tech giant. It isn't. Really. Thursday's rally was nothing short of a much-needed and well-deserved breath of fresh air for SPCE shareholders.InvestorPlace - Stock Market News, Stock Advice & Trading TipsDespite the Nasdaq Composite index having blasted through its February all-time high more than...
LAKEWOOD, Colo., July 17, 2020 /CNW/ - Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) ("Energy Fuels" or the "Company"), the largest uranium mining company in the United States, is pleased to announce the recent elimination of a portion of the Company's debt, confirmation of 2020 uranium production guidance, and updates on the value of the Company's significant uranium and vanadium inventories. On July 14, 2020, the Company completed the partial cash redemption of its floating rate convertible unsecured subordinated debentures (the "Debentures") as previously announced on June 11, 2020. On July 14, the Company distributed Cdn$10,430,000 of cash to holders of the Debentures (as of July 8, 2020)....
Norwegian Cruise Line Holdings (NCLH) has announced that it has priced its $250M offering of 16,666,667 ordinary shares at a price to the public of $15.00 per share. Shares in NCLH plunged 16% in Thursday’s trading, bringing the share price down to $15.61.NCLH has also granted the underwriters an option to purchase up to 2,500,000 of additional ordinary shares, which must be exercised on or before August 17, 2020.The offering is expected to close on July 21, 2020, subject to customary closing conditions. The company says it expects to use the net proceeds from the offering for general corporate purposes.J.P. Morgan, Citigroup, Goldman Sachs & Co. LLC, Barclays, Mizuho Securities and UBS Investment Bank are acting as joint book-running managers.NCLH, which operates a combined fleet of 28 ships, has seen shares plunge 73% year-to-date due to the fallout from Covid-19 on the tourism industry.However the stock maintains a cautiously optimistic Moderate Buy Street...
(Bloomberg) -- Sanofi is studying potential acquisitions of U.S. biotechnology companies including Principia Biopharma Inc. as it seeks innovative treatments for clinical areas including multiple sclerosis and immune disorders, people with knowledge of the matter said.The French drugmaker is working with advisers to study potential deals, the people said, asking not to be identified because the information is private.Chief Executive Officer Paul Hudson, who joined last year, is seeking to rejuvenate Sanofi by focusing on fast-growing areas where new medicines command high prices. There’s no certainty the deliberations will lead to a transaction, according to the people.Sanofi shares were little changed early Friday in Paris.Sanofi already has a partnership with Principia Biopharma to develop a treatment for central nervous system diseases. Principia Biopharma rallied in February after the experimental medicine succeeded in a mid-stage study and Sanofi’s CEO said it could grab half of the $20 billion market for multiple sclerosis...
